MedTrace Logo

Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage

NCT00487461 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-11-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether treatment with a drug called Simvastatin prevents and improves outcome in patients who have Subarachnoid bleeding. Simvastatin is currently approved for the treatment of high cholesterol levels.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage
  • Cerebral Vasospasm

Interventions

DRUG

Simvastatin 40 mg

Comparing two doses of Simvastatin to placebo

DRUG

Placebo

Placebo tablet

DRUG

Simvastatin 80 mg

Comparing two doses of Simvastatin to placebo

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Ben Z. Roitberg, MD · Assnt Prof. Univ. of Illinois at Chicago, Dept of Neurosurgery

  • Ali Alaraj, MD · Clinical Fellow Department of Neurosurgery

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-02-28
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487461 on ClinicalTrials.gov